Track topics on Twitter Track topics that are important to you
LEAMINGTON, ONTARIO -- (Marketwired) -- 03/08/17 -- In light of recent media coverage, Aphria Inc. ("Aphria" or the "Company") (TSX VENTURE: APH)(OTCQB: APHQF) today issued the following statement with respect to its ongoing commitment to providing pharmaceutical-grade cannabis that is free of chemical pesticides.
Vic Neufeld, Chief Executive Officer of Aphria, said, "Aphria has always held itself to the highest standards when it comes to the cultivation and production of medical cannabis. As part of this, we made a strategic investment in a state-of-the-art greenhouse in Leamington, Ontario, which enables us to produce medical cannabis that meets our exacting standards of quality, consistency, and safety."
"Aphria is committed to product integrity through every step of the growing process. We make our own fertilizer, which significantly reduces the risk of unwanted chemicals that can be found in 'pre-mixed' fertilizers. Additionally, we do not use chemical pesticides in the production of medical cannabis; we only use biological controls in the Leamington greenhouse. To be clear, Aphria has never supported the use of Myclobutanil."
"Since Aphria was founded, we have enforced a strict Quality Management Program that continuously tests for pesticides, including Myclobutanil. We closely monitor all suppliers to ensure that any products used meet or exceed the minimum standards set to comply with Health Canada's regulations. As we noted in December, we support the use of independent evaluations and testing of medical cannabis as a necessary measure to protect the safety of Canadians."
"In all, Aphria has adopted pharmaceutical-grade quality assurance and quality control processes, many of which are over and above what is required by Health Canada. We recognize that patients rely on a safe and high quality product to meet their medical needs and it is critically important that all products sold through the ACMPR adhere to the strict guidelines established by Health Canada to ensure that their needs are met."
"Aphria management has over 35 years of experience in agriculture and 20 years in the pharmaceutical space, we don't need to rely on chemicals because we know how to grow naturally."
Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit www.Aphria.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, estimated margins, timing for completion of final TSX approval, expectations for future growing capacity and costs, the completion of any capital project or expansions, any commentary related to the legalization of marijuana and the timing related thereto, expectations of Health Canada approvals and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange (the "Exchange") nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.Contacts: Aphria Inc. Mr. Vic Neufeld Chief Executive Officer 1-844-427-4742 NEXT ARTICLE
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...